Sino Biopharmaceutical Limited (SBMFF) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Wan Chai, Hong Kong. Le PDG actuel est S. Y. Tse.
SBMFF a date d'introduction en bourse 2010-02-22, 24,379 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $13.58B.
Sino Biopharmaceutical Limited is a Hong Kong-incorporated research and development pharmaceutical conglomerate operating in China since 2000. The company develops and commercializes a diverse portfolio of pharmaceuticals across multiple therapeutic areas, including oncology, cardio-cerebral vascular, hepatitis, orthopedic, and respiratory medicines, as well as innovative chemical pharmaceuticals and parenteral nutritional products. Beyond pharmaceutical manufacturing, Sino Biopharmaceutical operates an integrated healthcare ecosystem comprising hospital operations, optometry services, health food production, pharmaceutical distribution, and medical technology consulting. The company organizes its operations through three main segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others, generating revenue from drug sales, healthcare services, and strategic investments.
